Hyaluronic Acid Binding Peptides As Therapeutics and Cosmetics
Our novel peptide design platform helps to overcome the limitations of hyaluronic acid utility in cosmetic and therapeutic applications by forming stabilized gels.
Contact About This
Opportunity
The Problem
Hyaluronic acid (HA) is a naturally occurring molecule vital for hydration and structural support in the skin, joints, and eyes. Despite its widespread use in topical formulations, existing solutions provide HA only superficially and temporarily due to its inability to effectively penetrate the skin’s protective barrier. Even advanced formulations using varied molecular sizes cannot overcome core biological limitations like enzymatic degradation and poor cellular receptor binding. As a result, current approaches lack the targeted mechanisms needed to effectively absorb HA and ensure its functional retention.
The Solution
Unlike passive formulations, our hyaluronic acid binding peptide technology operates within the extracellular matrix, anchoring HA molecules to increase effective water uptake and retention. This active delivery mechanism enhances both penetration and functional availability of HA compared to HA alone. These peptides act as boosters that enhance the effectiveness of topical HA products and uniquely stabilize injectables by facilitating deeper interaction with the skin’s biology for longer-lasting benefits. Their ability to sustain HA retention and enable HA promoter release makes this technology a strong candidate for advanced biomaterials, pharmaceuticals, and next-generation skincare applications.
The Opportunity
The global hyaluronic acid market is projected to reach an estimated $17 billion by 2034, driven by a sustained growth in skincare and medical aesthetics. Due to the limited bioavailability and transient effects of current topical HA products, there is a growing demand for enhanced delivery systems that ensure deeper penetration and longer-lasting functional benefits of HA.
Status
In preclinical studies, our peptide technology demonstrated enhanced target engagement and efficacy, binding HA 3 to 4 times more effectively than commercial standard HA-binding peptides. With sustained HA retention, controlled release, and tunable properties, these peptides are strong candidates for cosmetic and skincare applications.
Meet the Team
Alejandro Rodriguez MBA, MS
External
Kyle Koss PhD
Assistant Professor
External
External
Peter Nestler PhD
Mentor
Tech Launch Arizona
Tech Launch Arizona
Contact us today.
Talk to a Tech Launch Arizona Venture
Development Manager to learn more and get connected to the inventor.
Check out more Pharma startups.
View All Startups & Inventions
Our novel gene editing removes the immunogenicity of human Pluripotent Stem Cells upon implantation into human organs. We have chosen Type 1 Diabetes as the initial indication to demonstrate the potential of our platform.
Our data-driven platform integrates high-throughput analytics and AI for next-generation drug discovery. We leverage novel insights into the foundational biologic pathways of neurodegenerative diseases to discover, evaluate, and develop disease-modifying therapeutics for Alzheimer’s disease, frontotemporal dementia (FTD) , amyotrophic lateral sclerosis (ALS), and other degenerative diseases of the nervous system.
Safe Lactobacillus-based synthetic biologic as a colonization resistance agent of, and oral vaccine for, Clostridioides difficile infection (CDI).
We offer a novel topical treatment for ocular degeneration that restores neuronal function and vision with a simple eye drop.